A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults
- Conditions
- Influenza
- Interventions
- Other: Sodium Chloride, 0.9%Biological: Influenza Virus Quadrivalent Inactivated VaccineBiological: VRC-FLUNPF099-00-VP (H1ssF_3928)
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-01-03
- Target Recruit Count
- 30
- Registration Number
- NCT05755620
- Locations
- 🇺🇸
Duke Vaccine and Trials Unit, Durham, North Carolina, United States
Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 90
- Registration Number
- NCT05750459
- Locations
- 🇺🇬
Makerere University - Infectious Diseases Institute, Kampala, Uganda
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2025-01-06
- Target Recruit Count
- 450
- Registration Number
- NCT05740982
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States
🇺🇸Duke Vaccine and Trials Unit, Durham, North Carolina, United States
Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC
- Conditions
- Monkeypox
- Interventions
- Biological: MVA-BN vaccine
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 500
- Registration Number
- NCT05734508
- Locations
- 🇨🇩
Institut National de Rescherche Biomédicale (INRB), Kinshasa, Congo, The Democratic Republic of the
🇨🇩L'Hôpital Général de Référence de Tunda, Tunda, Congo, The Democratic Republic of the
🇨🇩L'Hôpital Général de Référence de Kole, Kole, Congo, The Democratic Republic of the
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
- Conditions
- Acute HIV Infection
- Interventions
- Other: PlaceboBiological: VRC07-523LSDrug: ARTBiological: PGT121.414.LS
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 48
- Registration Number
- NCT05719441
- Locations
- 🇺🇸
3203, Greensboro CRS, Greensboro, North Carolina, United States
🇺🇸2701, Northwestern University CRS, Chicago, Illinois, United States
🇺🇸2702, Rush University CRS, Chicago, Illinois, United States
Transcutaneous Vagus Nerve Stimulation (tcVNS) in JIA
- Conditions
- Juvenile Idiopathic Arthritis (JIA)
- Interventions
- Device: Active tcVNS or Sham tcVNSDevice: Active tcVNS
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 100
- Registration Number
- NCT05710640
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Nemours Children's Health: Department of Pediatric Rheumatology, Orlando, Florida, United States
🇺🇸University of Chicago, Comer Children's Hospital, Chicago, Illinois, United States
Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine
- Conditions
- Response To Dengue Exposure
- Interventions
- Drug: rDENdelta30/31-7164
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 200
- Registration Number
- NCT05691530
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
- Conditions
- Epstein-Barr Virus InfectionInfectious MononucleosisHerpesvirus
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 1000
- Registration Number
- NCT05683834
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Daratumumab in Primary Antiphospholipid Syndrome
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-11-29
- Target Recruit Count
- 22
- Registration Number
- NCT05671757
- Locations
- 🇺🇸
NYU Langone, New York, New York, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
- Conditions
- HIV-1-infection
- Interventions
- Drug: Long acting CAB injectable + long acting RPV injectableDrug: Once daily CAB tablet + RPV tablet
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 90
- Registration Number
- NCT05660980
- Locations
- 🇺🇸
Site 5030, Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States
🇺🇸Site 6501, St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States
🇧🇼Site 12701, Gaborone CRS, Gaborone, Botswana